The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
 
Adrian Gerard Murphy
Research Funding - Agios; Bristol-Myers Squibb; Halozyme; Incyte
 
Rosalind Walker
No Relationships to Disclose
 
Eric R. Lutz
No Relationships to Disclose
 
Rose Parkinson
No Relationships to Disclose
 
Nita Ahuja
No Relationships to Disclose
 
Lei Zheng
Stock and Other Ownership Interests - Z and L International Medical
Consulting or Advisory Role - AstraZeneca; Biosynergies; Merck; Merrimack; novarock
Research Funding - Amgen; Bristol-Myers Squibb; Gradalis; Halozyme; ITeos Therapeutics; Merck
Patents, Royalties, Other Intellectual Property - GVAX, licensed to Aduro Biotech.
 
Elizabeth M. Jaffee
Consulting or Advisory Role - Adaptive Biotechnologies; CStone Pharmaceuticals; Dragonfly Therapeutics; Genocea Biosciences; Incyte
Research Funding - Aduro Biotech; Amgen; Bristol-Myers Squibb; Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genocea Biosciences; MedImmune
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals; Bayer/Onyx
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Intensity Therapeutics; Merck (Inst); Syndax (Inst)